CD300 family members are immunoglobulin superfamily receptors that regulate immune cell function through either activating or inhibitory signals. Among them, CD300a is a prototypical inhibitory receptor, highly expressed in both myeloid and lymphoid lineages, and plays a pivotal role in the pathogenesis of inflammation and tumor immunity. CD300a transduces inhibitory signals in several immune cells—including mast cells, eosinophils, monocytes, dendritic cells (DCs), neutrophils, and natural killer (NK) cells—by recruiting SHP-1 phosphatase to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and suppressing activation pathways such as Toll-like receptor (TLR)-MyD88 and FcεRI signaling. Recent studies suggest that tumor cells may hijack CD300a-associated pathways to establish an immunosuppressive microenvironment that facilitates immune evasion, tumor survival, and potentially metastatic spread. Proposed mechanisms include reduced DC-mediated type I interferon (IFN) production, diminished NK cell cytotoxicity, and negative regulation of mast cell– and eosinophil-dependent anti-tumor responses. Although some of these findings are derived from in vivo models, the cumulative evidence positions CD300a as a critical immune checkpoint in tumor-associated immune regulation. In addition to its established roles in hematologic malignancies—including chronic lymphocytic leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia—CD300a has also been implicated in modulating tumor-associated immune responses in other pathological contexts. While most studies emphasize its immune cell–mediated effects, emerging evidence suggests that CD300a may directly influence tumor progression by regulating immune homeostasis, intracellular signaling, and tumor microenvironment interactions. Collectively, these findings establish CD300a as a pleiotropic immunoregulatory molecule in both hematologic and non-hematologic malignancies, underscoring the need to further explore its broader relevance and therapeutic potential in cancer immunology.
CD300家族成员是免疫球蛋白超家族受体，通过激活性或抑制性信号调控免疫细胞功能。其中，CD300a是典型的抑制性受体，在髓系和淋巴系细胞中高表达，在炎症及肿瘤免疫的发病机制中发挥关键作用。CD300a通过招募SHP-1磷酸酶至免疫受体酪氨酸抑制基序（ITIM），抑制Toll样受体（TLR）-MyD88和FcεRI等激活通路，从而在肥大细胞、嗜酸性粒细胞、单核细胞、树突状细胞、中性粒细胞和自然杀伤细胞等多种免疫细胞中传递抑制信号。最新研究表明，肿瘤细胞可能劫持CD300a相关通路以建立免疫抑制微环境，从而促进免疫逃逸、肿瘤存活及潜在转移扩散。其机制可能包括降低树突状细胞介导的I型干扰素产生、削弱自然杀伤细胞毒性，以及对肥大细胞和嗜酸性粒细胞依赖性抗肿瘤反应的负向调控。尽管部分发现源于体内模型，但累积证据表明CD300a在肿瘤相关免疫调控中扮演着关键免疫检查点的角色。除在慢性淋巴细胞白血病、急性淋巴细胞白血病和急性髓系白血病等血液系统恶性肿瘤中的明确作用外，CD300a在其他病理背景下也被证实参与调控肿瘤相关免疫应答。尽管多数研究聚焦于其免疫细胞介导的效应，新近证据提示CD300a可能通过调节免疫稳态、细胞内信号传导及肿瘤微环境相互作用，直接影响肿瘤进展。综上所述，这些发现确立了CD300a在血液系统与非血液系统恶性肿瘤中作为多效性免疫调节分子的地位，凸显了进一步探索其在肿瘤免疫学中广泛相关性及治疗潜力的必要性。
CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity
肿瘤(癌症)患者之家